Wide Ranks

BCTXW

BriaCell Therapeutics Corp.

0.3450

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.49 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 862089 Total Cash Per Share 0.0470 Total Debt
Total Debt To Equity Current Ratio 0.49 Book Value Per Share -0.1300
All Measures
Message Board Id finmb_262266102 Fax 604-921-1898 City West Vancouver
Uuid 31b8333c-9e5f-3b4b-84e5-1498a50a3f49 Previous Close 0.2899 Book Value -0.1300
Beta 1.82 Volume 204875 Fifty Two Week Low 0.2301
Total Cash Per Share 0.0470 Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -4791466 Trailing Peg Ratio None Total Cash 862089
Trailing PE 0.0000 Regular Market Previous Close 0.2899 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 0.2899 Free Cashflow -10834774
State BC Dividend Yield 0.00 % Return On Assets -1.26
Time Zone Short Name EST Day Low 0.2301 Address1 Bellevue Centre
Target High Price 0.0000 Price Hint 4 Website https://briacell.com
Forward Eps 0.0000 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 21.40 % Is_sp_500 False Regular Market Day High 0.3450
Profit Margins 0.00 % Fifty Two Week High 0.3450 Day High 0.3450
Regular Market Open 0.2899 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Operating Cashflow -24126128 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 False Market Cap 0.0000
Zip V7T 2X1 Quote Type EQUITY Industry Biotechnology
Long Name BriaCell Therapeutics Corp. Regular Market Day Low 0.2301 Current Price 0.3450
Address2 Suite 300 235 -15th Street Financial Currency USD Current Ratio 0.49
Industry Disp Biotechnology Country Canada Float Shares 14 M
Forward PE 0.0000 Regular Market Volume 204875 Ebitda -33246180
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BriaCell Therapeutics Corp.

, a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.

Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.

It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.

BriaCell Therapeutics Corp.

is based in West Vancouver, Canada.